Stockreport

Innate Pharma Reports Full Year 2025 Financial Results and Business Update

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options curre [Read more]